Dr. Stephen Worthley, Ph.D., director of the cardiac cath labs at Royal Adelaide Hospital at the University of Adelaide in Australia, and co-principal investigator of Medtronic's recently launched international drug-filled stent (DFS) clinical trial, explains DFS the new technology. This was among the top innovations presented at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting.
VIDEO: How to Treat CTOs and Complex PCI Cases
A discussion with Khaldoon Alaswad, M.D., director, cardiac catheterization lab, Henry Ford Hospital, on treating chronic total occlusions (CTOs) and other complex PCI cases. Watch the VIDEO: Treating Chronic Total Occlusions with Bill Lombardi, M.D., director of complex coronary artery interventions at the University of Washington. Read the article "How to Tackle Coronary CTOs."
Todd Brinton, M.D., clinical associate professor and consulting associate professor of bioengineering at Stanford University Medical Center, explains balloon-based lithoplasty as a new alternative for treating heavily calcified coronary and peripheral vascular disease lesions. The technology was among the new innovations at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting.
Manesh Patel, M.D., associate professor of medicine, and director of interventional cardiology and the cath labs at Duke University, explains the innovations in interventional heart failure technologies, including the Aortix percutaneous heart pump. This was among the innovations presented at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting. Read more on this device.
Dean Kereiakes, M.D., medical director of The Christ Hospital Heart and Vascular Center, and a lead investigator for both the ABSORB and SYNERGY stent trials, discussed the latest developments in bioresorbable stent technology. Bioresorbable stent technology was among the top innovations presented at the 2015 Transcatheter Cardiovascular Therapeutics (TCT) annual meeting. Read the article "FDA Approves First Totally Bioresorbable Stent."
DAIC Editor Dave Fornell shares some of the most innovative new technologies shown on the expo floor and discusses in sessions at the Society of Cardiovascular Computed Tomography (SCCT) 2015 annual meeting.
Interview with James Min, M.D., Professor of Radiology and Medicine and Director of Dalio Institute of Cardiovascular Medicine, Weill Cornell, New York Presbyterian Hospital. Watch the VIDEO “Early U.S. Experience With FFR-CT in Evaluating ED Chest Pain Presentation.” A discussion with Simon Dixon, M.D., MBChB, on the use of fractional flow reserve-computed tomography (FFR-CT) to evaluate chest pain patients in the emergency departmenat Beaumont Hospital in Royal Oak, Mich. Read the article "What is New in FFR Technology."
Interview at the American Society of Echocardiography (ASE) annual meeting with Federico Asch, M.D., M.D., FACC, FASE, associate director of the echocardiography core lab at Medstar Health Research Institute and assistant professor of medicine (cardiology) at Georgetown University. He explains how ultrasound might have a roll in the future for breaking up clots and targeted delivery of gene and drug therapies.
Interview with Steve Goldstein, M.D., director, noninvasive lab, Medstar Washington Heart Institute, Washington, D.C., on the uses of echo guidance for interventional procedures in the cath lab.
Role of Interventional Echcardiography in Transcatheter Structural Heart Procedures — Rebecca Hahn, M.D., Columbia University Medical Center, is an expert in the new subspecialty of interventional echo and shares her insights at the Cardiovascular Research Foundation's (CRF) Transcatheter Valve Therapies (TVT) conference in Chicago in June.
Interview with Ted Feldman, M.D., FACC, MSCAI, FESC, cardiac cath lab director, Evanston Hospital, North Shore Health System, and principle investigator, Everest II MitraClip U.S. pivotal trial, at the Transcatheter Valve Therapies 2015 meeting. Watch the VIDEO “Advances and Future Directions for Transcatheter Valves.”
Interview with Juan Granada, M.D., executive director and chief scientific officer of the Cardiovascular Research Foundation's Skirball Center for Innovation, at the Transcatheter Valve Therapies 2015 meeting. Read the article "Transcatheter Mitral Valve Replacement Devices in Development."
Interview with Charanjit Rihal, M.D., chief of cardiology and professor of medicine, Mayo Clinic, at the Transcatheter Valve Therapies 2015 meeting.
In 2015, the FDA approved the first two drug-coated balloons for the U.S. market to treat peripheral artery disease in the SFA. Doug Drachman, M.D., Mass General Hospital, who served a the site principal investigator for the Lutonix balloon trial, explains his experiences and insights with these devices in an interview at ACC 2015. Read the article “Drug-eluting Balloons Enter the U.S. Market.”
Hear the latest trends and news on interventional cardiology from the American College of Cardiology (ACC) 2015 meeting in an interview with John Reilly, M.D., FACC, vice chairman of cardiology, Ochsner, New Orleans, and chairman of PR, SCAI.
DAIC Editor Dave Fornell shares his picks of the most interesting new devices and advances in cardiovascular technology shown on the expo floor at the 2015 American College of Cardiology (ACC) meeting.
Doug Drachman, M.D., Mass General Hospital Institute of Heart, Vascular and Stroke Care, explains how to prevent and manage access site complications, use of vascular closure devices and how to aid patient ambulation following PCI.
Ziad Ali, M.D., senior scientist at the Cardiovascular Research Foundation (CRF), discusses the current trials and future possibilities of intravascular near-infrared spectroscopy imaging to identify and pre-treat vulnerable plaque.
DAIC Editor Dave Fornell offers his choices of the most innovative new cardiovascular technologies discussed in sessions and shown on the expo floor at the Transcatheter Cardiovascular Therapeutics (TCT) 2014 meeting.
DAIC Editor, Dave Fornell, interviews Jim Hermiller, M.D., FACC, director of interventional cardiology, St. Vincent Heart Center-Indiana, and a principle investigator in the Absorb III Trial. Read the article "FDA Approves First Totally Bioresorbable Stent."
John Stevens, chairman and CEO of HeartFlow, explains his company's computed tomography (CT)-based fractional flow reserve (FFR) assessment technology, which may eliminate the need for catheter-based FFR measurements.
Peter G. Maxim, Ph.D., assistant professor of radiation oncology at Stanford University, discusses stereotactic radiotherapy for renal sympathetic nerve ablation for the treatment of refractory hypertension, and some of the challenges involved, with Imaging Technology News Editorial Director Melinda Taschetta-Millane.
DAIC Editor Dave Fornell offers his choices of the most innovative new cardiovascular technologies shown on the expo floor at the American College of Cardiology (ACC) 2014 meeting.
Bioresorbable stent technology was one of the big interventional technologies discussed at the American College of Cardiology (ACC) 2014 meeting. Doug Drachman, M.D., Mass General Hospital, explains where the technology is today and what we will likely see in the future. Read the article "FDA Approves First Totally Bioresorbable Stent."
The biggest late-breaking news to come out of the American College of Cardiology (ACC) 2014 meeting was from the CoreValve High-Risk pivotal trial, which showed a transcatheter valve offers a 26 percent survival benefit over surgical valve replacement. Co-Principal Investigator David Adams, M.D., explained the impact of the trial.
A major disappointment earlier this year was the announcement by Medtronic that its renal denervation system failed to meet its primary endpoint for efficacy in the U.S. SYMPLICITY HTN-3 trial. Michael Jaff , D.O., worked as part of the core lab for the trial and explains the trial outcomes and the future of renal denervation technology.
DAIC Editor Dave Fornell offers his choices of the most innovative new cardiovascular technologies discussed in sessions and shown on the expo floor at the Transcatheter Cardiovascular Therapeutics (TCT) 2013 meeting.
Scott Lim, M.D., director of the Heart Valve Center at the University of Virginia Medical Center, investigator in the EVEREST and COAPT trials, discusses the MitraClip transcatheter mitral valve repair system at TCT 2013. The device recieved FDA clearance a couple days before TCT.
Herbert Aronow, M.D., MPH, St. Joseph Mercy Hospital, Ann Arbor, and an active member of ACC and SCAI, explains the top interventional cardiology highlights at TCT 2013.
This animation, provided by Abbott, demonstrates how the FDA-cleared MitraClip transcatherer mitral valve repair system in implanted in the heart. The device requires a transeptal puncture and real-time guidance under angiography and 3-D transesophageal echo (TEE).
Related Transcatheter Mitral Valve Technology Content:
VIDEO: Update of Mitral Valve Repair and Replacement Technologies - Interview with Ted Feldman, M.D.
VIDEO: Transcatheter Mitral Valve Implantation in Practice and Technologies in Development - Interview with Adam Greenbaum, M.D.
VIDEO: Overview of Transcatheter Mitral Valve Repair Technologies — Interview with Ted Feldman, M.D.
VIDEO: Transcatheter Mitral Valve Technology, Anatomical Challenges — Interview with Juan Granada, M.D.
Ajay Kirtane, M.D., SD, chief academic officer at Columbia University Medical Center/New York Presbyterian Hospital, explains the key highlights regarding interventional cardiology at the American College of Cardiology (ACC) 2013. These included data on the use of cangrelor vs. clopidogrel during cath lab procedures, first U.S. reports on using the smaller Sapient XT transcatheter aortic valve, and the safety of using shorter duration dual-antiplatelet therapy with drug-eluting stents.
The American College of Cardiology (ACC) 2013 Scientific Session Committee Chairman Miguel Quinones, M.D., explains some of the key highlights from this year's meeting. Highlights included the impact of niacin on lowering cholesterol, new data on transcatheter aortic valve repair, and how mummies show atherosclerosis is not a modern disease.
DAIC Editor Dave Fornell explains his choices for the most innovative new technology on the expo floor at the American College of Cardiology (ACC) 2013. These include new angiography systems, dose monitoring software and technology integrations, an iPhone ECG monitoring device, ultrasound-aided CRT lead optimization, and new radiation protection aprons that are up to 50 percent lighter.
This short cine loop shows a 3-D/4-D transesophegeal echo (TEE) view of a transcatheter Amplatzer closure device used to seal an atrial septal defect (ASD) and the operation of a surgically implanted St. Jude Medical mechanical mitral valve. This type of complex ASD transcatheter repair is much easier to perform under real-time 3-D TEE guidance. This image was provided by GE Healthcare's Vivid E9 Breakthrough 2012 (BT12), which includes a 4-D transducer for TEE.
DAIC Editor Dave Fornell highlights the latest advancements that will impact cardiovascular imaging from the 2012 Radiological Society of North America (RSNA) meeting. RSNA is the largest medical imaging show in the world and most advancements are shown here first.
One-year results from the ADAPT-DES Trial were presented during TCT 2012. It examined patient hyporesponsiveness to clopidogrel and aspirin in a large-scale, prospective, multicenter study.
Mercy Hospital in Chicago developed an interventional program around its hybrid cath labs, fostering collaboration between interventional cardiologists, vascular surgeons and interventional radiologists. This collaboration has helped the hospital improve care and keep costs low in order to serve the Chicago South Side's low-income population. Read the article "Most Innovative Heart Centers: Chicago’s Mercy Hospital." There is also a related VIDEO about Mercy, "Developing a Hybrid Cath Lab Program."
Mercy Hospital in Chicago has developed a successful hybrid cath lab program where various specialties work together for the best, minimally invasive patient outcomes. Beyond the coronaries, this cath lab specializes in endovascular aortic stent grafting, peripheral vascular disease, embolization procedures and transcatheter heart valve replacements. Read the related article "Most Innovative Heart Centers: Chicago’s Mercy Hospital." Watch the related Mercy VIDEO "Mercy Hospital Develops Effective, Collaborative Interventional Program."
Results from the POSEIDON Trial were presented at TCT 2012. Data showed a positive strategy to prevent contrast-induced nephropathy in patients with renal impairment undergoing interventional catheterization procedures.
The PC Trial data presented at TCT 2012 looked at transcather PFO closure vs. medical therapy in preventing cryptogenic strokes.
The results of the FAME II Trial were presented at the 2012 Transcatheter Cardiovascular Therapeutics (TCT) meeting. The study showed the cost effectveness of fractional-flow reserve (FFR) therapy vs. standard medical therapy.